Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
OPT-80 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| OPT-80 | DRUG | - |
Inclusion Criteria: * Patients with CDAD Exclusion Criteria: * Patients with severe CDAD
OPT-80 is an investigational small molecule being developed for the treatment of diarrhea, specifically Clostridium difficile-associated diarrhea (CDAD). It is in Phase 2 clinical development and is not yet approved by the FDA.
OPT-80 is being developed by Merck & Company, Inc. (NYSE: MRK). The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with diarrhea.
OPT-80 is in Phase 2 clinical development. It has completed one Phase 2 trial, and it remains an investigational drug that has not been approved for commercial use.
OPT-80 has been studied in one completed Phase 2 clinical trial, identified as NCT00097422, titled 'OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD)'. This trial was conducted in the United States and enrolled adult patients with diarrhea.
No, OPT-80 is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for the treatment of diarrhea, and it has not yet received regulatory approval.